The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

The Executive Vice-President, Diagnostics, Africa at Roche Diagnostics, Dr. Allan Pamba stated this in a statement to ...

Executive Vice-President of Diagnostics, Africa, at Roche Diagnostics, Dr. Allan Pamba, has urged action against diabetes. He said November is World Diabetes Awareness month, noting non-communicable ...

Ontario is a prime location for domestic and international biomanufacturers looking to invest and bring their innovative ideas from lab to market,” said Vic Fedeli, Minister of Economic Development, ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

At Roche, our primary contribution to society is to develop medicines and diagnostics that significantly improve people’s ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...